Grew practitioner network to over 7,100 from 6,400 in 2022 Launched BioteRx, our new hormone and therapeutic wellness offerings Enhancing shareholder value with agreement to repurchase 18.4M founders’ shares in addition to a separate $20M share repurchase program Reaffirms 2024 financial guidance, with an acceleration in second half growth IRVING, Texas / Mar 12, 2024 / Business Wire / Biote (NASDAQ: BTMD), a leading... Read More

IRVING, Texas / Feb 27, 2024 / Business Wire / biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide fourth quarter and full year financial results on Tuesday, March 12, 2024, after the close of the market. A conference call to discuss the firm’s... Read More

Company to repurchase approximately 18.4 million Class A shares and Paired Interests at $4.17 per share IRVING, Texas / Feb 20, 2024 / Business Wire / biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced it has signed a binding term sheet with Dr. Gary S. Donovitz... Read More

IRVING, Texas / Jan 25, 2024 / Business Wire / biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that its Board of Directors has approved a $20 million share repurchase program of the Company's common stock. This approval grants Biote’s management the authority to... Read More

IRVING, Texas / Jan 17, 2024 / Business Wire / biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that management expects 2023 revenue and Adjusted EBITDA to be slightly below prior guidance. The Company had previously forecast that revenue and Adjusted EBITDA would be... Read More

Strategic and accretive transaction enables vertical integration of hormone product manufacturing IRVING, Texas / Jan 17, 2024 / Business Wire / biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced a definitive agreement to acquire F.H. Investments, Inc., d/b/a Asteria... Read More

IRVING, Texas / Jan 11, 2024 / Business Wire / biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Robert Peterson has been named Chief Financial Officer, effective January 8, 2024. Mr. Peterson will lead Biote’s finance operations, including accounting and... Read More

Achieves Progress in Test of Complementary Wellness Therapeutics Reiterates 2023 Financial Guidance IRVING, Texas / Nov 07, 2023 / Business Wire / Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced financial results for the third quarter ended September 30, 2023. Third Quarter 2023 Financial Highlights (All financial result... Read More

IRVING, Texas / Oct 24, 2023 / Business Wire / biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of hormone optimization, today announced the Company will provide third quarter financial results on Tuesday, November 7, 2023, after the close of the market. A conference call to discuss the firm’s results will be held Wednesday, November 8, 2023, at 8:30 a.m. ET. Conference Call Details The conference... Read More

Solid Second Quarter Revenue Growth Continued Progress to Optimize Capital Structure and Enhance Share Liquidity Expansive Strategic Approach Targeting Therapeutic Wellness and Men’s Health Categories IRVING, Texas / Aug 10, 2023 / Business Wire / Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced financial results for the second... Read More

IRVING, Texas / Jul 27, 2023 / Business Wire / biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of hormone optimization, today announced the Company will provide second quarter financial results on Thursday, August 10, 2023, after the close of the market. A conference call to discuss the firm’s results will be held Friday, August 11, 2023, at 8:30 a.m. ET. Conference Call Details The conference call... Read More

Leader in Hormone Education and Training Aims to Increase Awareness and Access to Testosterone Deficiency Therapy through Expanded Network of Urologists and Internal Medicine Practitioners IRVING, Texas / Jun 22, 2023 / Business Wire / biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading provider of hormone optimization, has announced the launch of a new Men’s Health Division with the mission of redefining... Read More

IRVING, Texas / Jun 08, 2023 / Business Wire / Biote (NASDAQ: BTMD) (the “Company,” “we” or “us”), a leading solutions provider in preventive healthcare through the delivery of personalized hormone therapy, today announced the expiration and results of its previously announced (i) offer to each holder of its outstanding warrants, each whole warrant exercisable for one share of Class A Common Stock, par value $0.0001 per... Read More

IRVING, Texas / Jun 05, 2023 / Business Wire / biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the pricing of an underwritten offering of 5,217,392 shares of its Class A common stock by one its stockholders at a price of $5.35 per share. The selling stockholder has granted the underwriter a 30-day option... Read More

IRVING, Texas / May 31, 2023 / Business Wire / biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced its participation at the following investor conferences: On June 6, 2023, Terry Weber, Biote’s Chief Executive Officer, and Samar Kamdar, Biote’s Chief Financial Officer, will present at 10:40 AM ET at... Read More

Ms. Puncochar to Drive Execution of Biote’s Strategic Sales and Marketing Initiatives IRVING, Texas / May 30, 2023 / Business Wire / biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced the appointment of Mary J. Puncochar as Chief Commercial Officer. In this role, Ms. Puncochar will lead Biote’s... Read More

New Initiative Targets Long-term Growth Opportunity in Men’s Health Company Launches Warrant Exchange Offer and Consent Solicitation Maintains 2023 Financial Guidance IRVING, Texas / May 09, 2023 / Business Wire / Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced financial results for the first quarter ended March 31, 2023. First... Read More

IRVING, Texas / May 09, 2023 / Business Wire / Biote (NASDAQ: BTMD) (the “Company,” “we” or “us”), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced that it has commenced an exchange offer (the “Offer”) and consent solicitation (the “Consent Solicitation”) relating to its (i) 8,397,624 outstanding public warrants (the “Public Warrants”) to purchase... Read More

IRVING, Texas / Apr 26, 2023 / Business Wire / biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the Company will provide first quarter financial results on Tuesday, May 9, 2023, after the close of the market. A conference call to discuss the firm’s results will be held Wednesday, May 10, 2023, at 8:30 a.m.... Read More

Mr. Denne to Accelerate Biote’s Expansion into Men’s Hormone Replacement Therapy Market IRVING, Texas / Apr 10, 2023 / Business Wire / Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced that John Denne has joined the Company as General Manager, Men’s Health Division. In this role, Denne will lead Biote’s sales initiatives to... Read More

Achieved Full Year 2022 Record Revenue and Adjusted EBITDA for Full Year 2022 Expect 2023 Revenue of $190-200 million and Adjusted EBITDA of $56-60 million Significantly Increased Trading Liquidity with Recent Successful Secondary Offering IRVING, Texas / Mar 28, 2023 / Business Wire / Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today... Read More

Study reports the patient also experienced “increased energy, recovery, and benefits to his sleep apnea” as well as being able to “remove supportive fracture hardware in one year” IRVING, Texas / Mar 27, 2023 / Business Wire / In a case study, a 54-year-old male patient with a spontaneous fracture and osteoporosis achieved an “almost complete recovery of osteoporosis” after one year of pelleted testosterone therapy and... Read More

IRVING, Texas / Feb 09, 2023 / Business Wire / Biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the Company will provide fourth quarter and full year financial results on Tuesday, March 28, 2023, after the close of the market. A conference call to discuss the firm’s results will be held Wednesday, March... Read More

biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the closing of its previously announced underwritten public offering of 8,500,000 shares of its Class A common stock by certain of its stockholders, including the full exercise of the underwriters’ option to purchase 1,108,695 shares of Class A common stock,... Read More

biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the pricing of an underwritten public offering of its Class A common stock by certain of its stockholders at a price to the public of $3.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions, are expected... Read More